Tempest Therapeutics (TPST) Boosts Cash With $4.6M Raise Ahead of Cancer Trial
Tempest Therapeutics, Inc. (NASDAQ:TPST) is a clinical-stage biotechnology company pioneering dual-action cancer therapies that combine direct tumor targeting…
Wall Street Is Sleeping on Tempest Therapeutics (TPST)—But Not For Long
Tempest Therapeutics, Inc. (NASDAQ:TPST) is a 2011-founded, Brisbane-based oncology innovator that has quietly risen from a niche research…